Novavax, Inc. Stock Nasdaq
Equities
US6700021040
Biotechnology & Medical Research
Sales 2024 * | 952M 1.3B | Sales 2025 * | 586M 797M | Capitalization | 1.83B 2.49B |
---|---|---|---|---|---|
Net income 2024 * | 18M 24.5M | Net income 2025 * | -116M -158M | EV / Sales 2024 * | 1.04 x |
Net cash position 2024 * | 837M 1.14B | Net cash position 2025 * | 704M 959M | EV / Sales 2025 * | 1.92 x |
P/E ratio 2024 * |
205
x | P/E ratio 2025 * |
-23.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.14% |
Latest transcript on Novavax, Inc.
Managers | Title | Age | Since |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |